Dr. Ibolya Rutkai-Green's lab at Tulane University focuses on understanding how aging affects the blood vessels in the brain. They study how reduced blood flow, especially in older mice, can lead to problems with the blood-brain barrier and increase the risk of neurodegenerative diseases like Alzheimer's. By combining advanced imaging techniques and various biological assays, the lab aims to uncover the mechanisms behind these vascular changes due to aging.

Dr. Gaurav Sahay's lab focuses on developing innovative gene therapy solutions for two major health issues: cystic fibrosis and inherited retinal degenerations. The lab works on creating advanced nanoparticle systems to deliver optimized mRNA and gene editing tools directly to targeted cells in the lungs and retina. By leveraging cutting-edge technologies such as microfluidics and AI-assisted design, the research aims to improve treatment effectiveness while minimizing invasiveness and side effects.

Dr. David Yule's research lab focuses on understanding the mechanisms behind saliva secretion in order to address conditions like dry mouth, which can severely affect quality of life. The lab employs a combination of experimental techniques and computer modeling to explore how salivary glands function normally and how these processes are disrupted in diseases such as Sjogren's syndrome. By investigating the cellular activities involved in saliva production, the lab hopes to develop new therapies for patients suffering from reduced saliva flow.

Dr. Daniela Salvemini's lab focuses on understanding how chemotherapy can impair cognition, a condition known as chemotherapy-induced cognitive impairment (chemobrain). The research investigates how molecules in the brain, particularly sphingosine-1-phosphate receptors, contribute to cognitive decline after chemotherapy. The goal is to find potential treatments that could lessen this side effect for cancer survivors.

Dr. Radojka Savic's lab at UCSF focuses on improving tuberculosis (TB) treatment by developing new drug regimens and diagnostics. The lab aims to enhance the accuracy of TB diagnosis through innovative blood tests that measure cell-free RNA, and to optimize treatment strategies using advanced modeling and animal studies. By collaborating with a multidisciplinary team, they seek to tackle the pressing global health challenge of TB, aiming for shorter and more effective treatment options.

Dr. Pavel A. Petukhov's lab focuses on developing new drugs to treat schistosomiasis, a disease caused by parasitic worms affecting over 200 million people worldwide. The research centers around a unique enzyme, thioredoxin glutathione reductase (TGR), which is crucial for the worm's survival but not present in humans. By inhibiting this enzyme, the lab aims to create effective treatments while avoiding drug resistance, a significant issue with the current medication.

The lab led by Dr. James J. Collins at UT Southwestern focuses on developing new therapeutic strategies to combat schistosomiasis, a disease caused by parasitic worms affecting millions worldwide. The team aims to discover and validate drug targets that can lead to the development of next-generation antischistosome therapies, addressing the urgent need for effective treatments due to rising drug resistance. By leveraging advanced techniques like RNA interference, they are identifying essential genes in schistosomes to pave the way for innovative drug discovery efforts.

Dr. Michal Laniado Schwartzman's lab at New York Medical College studies the relationship between obesity and cardiovascular diseases. The research focuses on understanding how a specific receptor, GPR75, interacts with a lipid mediator called 20-HETE to influence metabolic health. This work aims to uncover mechanisms that may lead to new treatments for obesity-related health issues.

Dr. Emily E. Scott's lab focuses on understanding human cytochrome P450 enzymes, which play a crucial role in drug metabolism and are also potential targets for treating various diseases. By using advanced structural and biochemical techniques, the lab aims to uncover the structure and function of these enzymes, providing insights that could lead to better drug design and therapies for both common and rare diseases. The research not only seeks to improve drug therapy but also to identify how mutations in these enzymes can lead to health issues.

Dr. Jia Zhou's lab at the University of Texas Medical Branch Galveston focuses on understanding cocaine use disorder (CUD) and exploring new treatments. The team is particularly interested in how serotonin receptors can be modulated to help reduce cravings and relapse in individuals struggling with CUD. They aim to develop novel compounds that improve serotonin receptor function as a potential therapy for CUD and related neuropsychiatric disorders.

Dr. Michael J. Sheedlo's lab focuses on understanding how the Clostridioides difficile Transferase (CDT) toxin works to infect host cells. They use advanced imaging techniques and biochemical methods to investigate the structure and function of CDT, aiming to find new ways to develop treatments for infections caused by this bacterium. By exploring how CDT interacts with cells, the lab seeks to uncover important details that could lead to better therapies for combating C. difficile infections.

Dr. Yi Shi's lab focuses on developing innovative therapies to combat COVID-19 using unique nanobody technologies. The lab aims to create ultrapotent drug candidate cocktails that can neutralize various strains of the SARS-CoV-2 virus. By utilizing advanced proteomics and engineering techniques, the lab is working toward designing cost-effective and effective treatments that can be easily administered, even through inhalation.

Dr. Hong-Yu Li's research at the University of Texas Health Science Center focuses on developing new drugs to target a protein called Skp2, which plays a significant role in cancer progression, particularly in prostate cancer. His lab is working on innovative drug candidates known as PROTACs that can effectively degrade Skp2 in cancer cells, potentially leading to improved treatments for patients with aggressive prostate cancer. By leveraging novel methods for drug development, the lab aims to bring new therapeutic options to clinical trials.

Dr. Adam Steven Smith's lab at the University of Kansas Lawrence focuses on understanding the effects of social loss on the brain, particularly in the context of losing a partner. Using a prairie vole model, the lab investigates how such losses impact emotional and motivational states, aiming to uncover the neurobiological mechanisms behind prolonged grief and develop potential therapeutic interventions. The research combines behavioral studies with neuroscience to provide insights into the brain's response to emotional trauma related to social connections.

Dr. Smrcka's lab studies how signals from G protein-coupled receptors (GPCRs) influence various cellular functions, particularly in heart cells. By exploring the complex interactions and pathways of GPCR signaling, the lab aims to uncover new ways that these receptors can control gene expression and heart growth, which could lead to better treatments for heart disease.

Dr. Hao Chen's lab studies how social environments affect nicotine addiction, especially among adolescents. By using a rat model, the lab explores the biological underpinnings of nicotine's appeal, even when it is initially aversive. This research could provide key insights into addiction treatment and prevention, as understanding these mechanisms may help in developing better public health strategies.

The lab focuses on understanding how social interactions affect alcohol consumption and dependence, particularly through the lens of the social neuropeptide oxytocin. By developing a preclinical model, the research aims to dissect the neurobiological mechanisms underlying alcohol-seeking behaviors in diverse social contexts. This work is especially relevant to addressing Alcohol Use Disorder (AUD), which significantly impacts public health.

Dr. Jeremy E. Rosenkranz's lab investigates the biological basis of social behavior, especially in the context of Autism Spectrum Disorder (ASD). His research focuses on how certain genes influence brain circuits responsible for social functions, particularly during adolescence, a critical time for social and neural development. By exploring the roles of specific proteins like neurexin and the interactions between different brain areas, his work aims to bridge the gaps between genetics, brain function, and social behavior.

Dr. Adebowale Adebiyi's lab focuses on understanding the role of specific sodium channels in kidney function, especially during neonatal acute kidney injury (AKI). The research aims to uncover how these channels influence blood flow in the kidneys and contribute to the severity of kidney damage after events such as hypoxia. By studying these mechanisms, the lab seeks to identify potential new therapies to mitigate kidney injury in newborns.

Dr. Richard S. Smith's research lab focuses on understanding how ion channel dysfunctions, particularly in sodium channels, affect brain development and lead to neurological disorders in children. By studying these processes in unique animal models, such as transient transgenic ferrets, the lab aims to uncover the biological origins of severe brain malformations and develop innovative RNA-based therapies that can intervene early in life to prevent long-term damage. Their work combines advanced experimental techniques with high-throughput screening methods to create effective treatments for complex neurodevelopmental diseases.